A methodology concern of the meta‐analysis of antiviral therapy for chronic hepatitis B virus infection in adults
Zhi‐Feng Zhang, Zhi‐Jun Duan – 16 January 2016
Reply
Anna S. Lok – 16 January 2016
Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo – 16 January 2016 – Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved.
Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo – 16 January 2016 – Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved.
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
Riccardo Lencioni, Thierry de Baere, Michael C. Soulen, William S. Rilling, Jean‐Francois H. Geschwind – 13 January 2016 – Transarterial chemoembolization (TACE) using lipiodol‐based regimens, including the administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta‐analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC.
Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma?
Tamar H. Taddei – 13 January 2016
Clinical advances in pediatric nonalcoholic fatty liver disease
Jeffrey B. Schwimmer – 11 January 2016
CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors
Ming Liu, Leilei Chen, Ning‐Fang Ma, Raymond Kwok Kei Chow, Yan Li, Yangyang Song, Tim Hon Man Chan, Shuo Fang, Xiaodong Yang, Shaoyan Xi, Lingxi Jiang, Yun Li, Ting‐Ting Zeng, Yan Li, Yun‐Fei Yuan, Xin‐Yuan Guan – 11 January 2016 – High‐grade tumors with poor differentiation usually show phenotypic resemblance to their developmental ancestral cells. Cancer cells that gain lineage precursor cell properties usually hijack developmental signaling pathways to promote tumor malignant progression. However, the molecular mechanisms underlying this process remain unclear.
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
Fred Poordad, Eugene R. Schiff, John M. Vierling, Charles Landis, Robert J. Fontana, Rong Yang, Fiona McPhee, Eric A. Hughes, Stephanie Noviello, Eugene S. Swenson – 11 January 2016 – Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver transplantation recurrence represents a high unmet medical need with no approved therapies effective across all HCV genotypes.